Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Dec;18(12):822-4.
doi: 10.4103/0972-5229.146321.

Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study

Reshma Basu  1 , Sunjay Pathak  2 , Jyoti Goyal  2 , Rajeev Chaudhry  2 , Rati B Goel  2 , Anil Barwal  2
Affiliations
Case Reports

Use of a novel hemoadsorption device for cytokine removal as adjuvant therapy in a patient with septic shock with multi-organ dysfunction: A case study

Reshma Basu et al. Indian J Crit Care Med. 2014 Dec.

Abstract

CytoSorb(®) (CytoSorbents Corporation, USA) is a novel sorbent hemoadsorption device for cytokine removal. The aim of this study was to examine the clinical use of CytoSorb(®) in the management of patient with septic shock. We used this device as an adjuvant to stabilize a young patient with multi-organ failure and severe sepsis with septic shock. A 36-year-old female patient was hospitalized with the complaints of malaise, general body ache, and breathing difficulty and had a medical history of diabetes mellitus type II, hypertension, obstructive sleep apnea, hypothyroidism and morbid obesity. She was diagnosed to have septic shock with multi-organ dysfunction (MODS) and a low perfusion state. CytoSorb(®) hemoadsorption column was used as an attempt at blood purification. Acute physiology and chronic health evaluation score, MODS score, and sequential organ failure assessment score were measured before and after the device application. CytoSorb application as an adjuvant therapy could be considered in septic shock.

Keywords: CytoSorb; hemoadsorption; septic shock; systemic inflammatory response syndrome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, CUB-Réa Network. Current epidemiology of septic shock: The CUB-Réa network. Am J Respir Crit Care Med. 2003;168:165–72. - PubMed
    1. Taniguchi T, Hirai F, Takemoto Y, Tsuda K, Yamamoto K, Inaba H, et al. A novel adsorbent of circulating bacterial toxins and cytokines: The effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia. Crit Care Med. 2006;34:800–6. - PubMed
    1. Schädler D, Porzelius C, Jörres A, Marx G, Meier-Hellmann A, Putensen C, et al. A multicenter randomized controlled study of an extracorporeal cytokine hemoadsorption device in septic patients. Crit Care. 2013;17:62.
    1. Taniguchi T, Kurita A, Mukawa C, Yamamoto K, Inaba H. Dose-related effects of direct hemoperfusion using a cytokine adsorbent column for the treatment of experimental endotoxemia. Intensive Care Med. 2007;33:529–33. - PubMed
    1. Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008;36:1573–7. - PMC - PubMed

Publication types